iShares MSCI Japan ETF vs State Street SPDR S&P Biotech ETF — how do they compare? iShares MSCI Japan ETF trades at $91.98, while State Street SPDR S&P Biotech ETF trades at $152.14. Which is the better fit depends on your goals.
| EWJ | XBI | |
|---|---|---|
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $96.97 | $164.28 |
52-Week Low | $71.81 | $85.16 |
Signals from Pluang's Aura AI — not financial advice
EWJ, the iShares MSCI Japan ETF, trades at $91.98, down 2.03% on the day. The technical outlook is bullish based on moving averages, with oscillators neutral. Key support lies at $92-$93 and resistance at $94-$95. Recent news highlights Japan's market dynamics, including currency intervention risks and pension fund shifts.
The ETF offers exposure to Japanese equities amid a weakening yen and potential government support. Risks include yen volatility and economic sensitivity. Analyst sentiment is mixed, with technical strength offset by currency and macroeconomic uncertainties.
XBI (SPDR S&P Biotech ETF) trades at $152.07, down 2.23% today, but maintains a bullish technical outlook with strong momentum indicators. The ETF has gained significant attention with a 17% monthly surge, driven by biotech sector strength and increased M&A activity. Analyst coverage shows a cautious stance with 100% hold rating, reflecting balanced risk-reward assessment amid sector volatility.
The biotech sector shows strong momentum with AI drug discovery advances and record M&A activity ($106 billion in 2026). While XBI offers high-beta exposure to small/mid-cap biotech growth, investors face elevated volatility and regulatory uncertainties. The equal-weight portfolio structure provides diversified exposure to sector innovation but requires tolerance for price swings.
Trailing returns across standard periods
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →